Needle-Stick Injury: Risk Stratification & Management

Contents

1. Overview
2. Learning objectives
3. What counts as a needle-stick or sharps injury?
4. Risk stratification
5. Immediate management
6. Post-exposure prophylaxis (PEP)
7. Follow-up
8. Prevention
9. Case example
10. References & further reading
11. Disclaimer

Overview

Needle-stick and other sharps injuries risk exposure to blood-borne viruses (BBVs) including HIV, Hepatitis B (HBV), and Hepatitis C (HCV). They occur most frequently in healthcare but also arise in community settings (e.g., discarded needles). Timely first aid, structured risk assessment, and evidence-based management reduce transmission risk.

Transmission risk (approximate after percutaneous exposure):

• HIV: ~0.3%
• HBV (if unvaccinated): ~6–30%
• HCV: ~1–3%

High-risk features:

• Deep percutaneous injury
• Hollow-bore needle, visible blood, large volume
• Source patient known/suspected BBV positive

Learning objectives

1. Define needle-stick/sharps injuries and when they are clinically significant.
2. Apply a structured, UK-aligned risk stratification to exposures.
3. Outline immediate management steps including first aid and baseline testing.
4. Determine when and how to start PEP for HIV and manage HBV/HCV exposures.
5. Implement prevention strategies and reporting pathways.

What counts as a needle-stick or sharps injury?

Any percutaneous injury with a used or potentially contaminated sharp (e.g., hypodermic needle, suture needle, scalpel, broken glass) or mucosal/broken-skin splash with potentially infectious fluid.

Remember: Hollow-bore needles and deep injuries carry higher risk than solid sharps or superficial scratches.

Risk stratification

Use these factors to categorise exposure (minimal/low / high) and guide investigations and PEP.

Exposure factor	Higher-risk indicators
Route	Deep percutaneous injury; mucosal exposure to blood/body fluids; broken skin contact
Device	Hollow-bore needle > suture needle/scalpel
Blood/volume	Visible blood on device; large volume; device used in vein/artery
Source patient	Known HIV/HBV/HCV positive; high-risk factors; unknown source in high-prevalence context
Time since use	Immediate post-use injury > found needle of uncertain timing (still assess)
Host factors	HBV non-immune; pregnancy (discuss risks/benefits of PEP); immunosuppression

Source testing (with consent): HIV Ag/Ab, HBsAg, HCV Ab (and RNA if indicated).

Immediate management

First aid

• Wash area gently with soap and running water.
• Do not scrub or suck; do not use harsh chemicals.
• Encourage slight bleeding; irrigate mucous exposures with water or saline.

Report & document

• Notify supervisor and Occupational Health / attend ED promptly.
• Record time, device, depth, visible blood, source details if known.
• Complete incident reporting per local policy.

Baseline actions

• Check tetanus status and HBV immunisation history.
• Baseline bloods (exposed person): HIV, HBsAg/anti-HBs (if needed), HCV Ab ± RNA per local pathway.
• Seek senior/ID advice for complex cases (e.g., pregnancy, renal disease, drug interactions).

Time-critical: If HIV PEP is indicated, aim to start as soon as possible (ideally < 1 hour, up to 72 hours).

Post-exposure prophylaxis (PEP)

HIV PEP

• Indicated when the source is known or strongly suspected to be HIV-positive and exposure is significant.
• Start urgently (ideally < 1 hour; do not exceed 72 hours).
• UK regimen (per BHIVA era):
• Tenofovir disoproxil + Emtricitabine plus an integrase inhibitor (e.g., Raltegravir or Dolutegravir) for 28 days. Follow local formulary.
• Arrange follow-up HIV testing at baseline, ~6 weeks, ~12 weeks, and ~6 months (per local protocol/4th-gen assays).

Hepatitis B

Exposed person status	Recommended action
Fully vaccinated, known responder (anti-HBs ≥10 mIU/mL)	No further action typically required; consider booster if titres unknown and high-risk exposure.
Partially vaccinated / response unknown	Give booster and check anti-HBs according to local policy.
Unvaccinated	Start HBV vaccine series. Consider HBIG if source is HBsAg-positive or high risk.

Hepatitis C

• No proven post-exposure prophylaxis.
• Baseline and follow-up testing (HCV Ab and/or RNA). Early referral if seroconversion occurs.

Follow-up

• Book an Occupational Health or GP review within 48–72 hours.
• Schedule repeat serology per local/UK pathways:
  • HIV: typically at ~6 and ~12 weeks, and ~6 months.
  • HBV: per vaccination/antibody response schedule.
  • HCV: consider HCV RNA at ~3 months; antibody/RNA at ~6 months.
• Provide psychological support and counselling; discuss work adjustments if needed.
• Ensure documentation, incident learning, and sharps safety review.

Prevention

Safe sharps practices

• Avoid recapping. Activate safety devices immediately after use.
• Dispose of sharps promptly into approved containers at the point of care.
• Use safety-engineered devices where available.

Systems & training

• Maintain HBV immunisation for all relevant staff.
• Ensure easy access to PEP and clear out-of-hours pathways.
• Foster a report-without-blame culture; audit incidents and provide feedback learning.

Case example

Scenario: A junior doctor sustains a hollow-bore needle-stick from a used cannula in a patient with known HIV infection.

1. Immediate first aid (wash; do not scrub; encourage bleeding).
2. Notify senior and Occupational Health; document the incident.
3. Urgently initiate HIV PEP (within 1 hour) after risk assessment.
4. Baseline and source bloods: HIV Ag/Ab, HBsAg, HCV Ab (± RNA per policy).
5. Arrange follow-up testing and counselling; check HBV immunity.

References & further reading

• RCEMLearning: Needle-Stick Injury Module
• RCEM: Care of Patients Exposed to BBVs (guideline PDF)
• BHIVA HIV Post-Exposure Prophylaxis Guidance
• UKHSA: BBVs in Healthcare Workers
• NICE: Evidence & pathways (see local policies aligned to UK guidance)

Always follow your trust and local microbiology advice; drug choices and testing intervals may vary with updates and availability.

Disclaimer

This webpage is for educational purposes only and does not constitute medical advice.